Startups
Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc.
Overview
Location
United States, California, La Mesa
Employees
11-50
Founded date
2012
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 30, 2021 | REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER | SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes. W... |